Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama

Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly's oral GLP-1, orforglipron

Company plans to create 3,450 manufacturing and construction jobs at Lilly's ninth U.S. manufacturing site announced since 2020

Read more at prnewswire.com